Gyre Therapeutics (GYRE) Inventory (2022 - 2026)

Gyre Therapeutics (GYRE) has 5 years of Inventory data on file, last reported at $11.4 million in Q1 2026.

• Inventory for Q1 2026 came in at $11.4 million, up 44.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.4 million (up 44.1% YoY), and the FY2025 annual result was $10.2 million, up 60.5% from the prior year.
• Inventory climbed to $11.4 million in Q1 2026 per GYRE's latest filing, from $10.2 million in the prior quarter.
• Over five years, Inventory peaked at $11.4 million in Q1 2026 and troughed at $4.3 million in Q4 2023.
• A 5-year average of $7.3 million and a median of $6.4 million in 2024 frame the typical range for Inventory.
• The sharpest annual moves came in 2023 and 2025: Inventory plunged 30.07% in 2023, then soared 60.5% in 2025.
• A 5-year view of Inventory shows it stood at $6.1 million in 2022, then plunged by 30.07% to $4.3 million in 2023, then soared by 48.03% to $6.3 million in 2024, then surged by 60.5% to $10.2 million in 2025, then rose by 11.61% to $11.4 million in 2026.
• Business Quant data shows GYRE's Inventory at $11.4 million in Q1 2026, $10.2 million in Q4 2025, and $8.9 million in Q3 2025.